Wegovy Geriatric (65+): Caregiver Administration Guidance

Print or save as PDFOpens the printable training log and your print dialog. No sign-up.

Who can give the injection

The Wegovy label includes caregivers in the required training for the prescribed injection presentation. It says to tell patients and their caregivers which presentation they will receive (a single-dose pen or syringe, or the FlexTouch single-patient-use pen), to train them on proper injection technique for that presentation before starting, and to retrain them if the prescribed presentation changes [1]. After training, a patient may self-inject if the healthcare provider determines it can be done properly. The label makes one exception: WEGOVY FlexTouch is not recommended for self-administration by people who are visually impaired [1].

Wegovy injection is indicated for adults with obesity, adults with overweight plus at least one weight-related condition, adults with established cardiovascular disease plus obesity or overweight, and adults with noncirrhotic MASH with moderate to advanced fibrosis [1].

How a caregiver gives a Wegovy injection

• Timing. The label says Wegovy injection is given once weekly, on the same day each week, at any time of day, with or without meals [1].
• Check the liquid. The label says to inspect the injection before each administration and to use it only if the solution is clear, colorless and contains no particles [1].
• Site. Abdomen, thigh or upper arm; the label says the time of day and the injection site can be changed without a dose adjustment [1].
• Device. The label says to consult the Instructions for Use for the prescribed presentation, and to arrange training for the specific presentation the patient receives [1].
• Never share. The label says a FlexTouch pen must never be shared between patients, even if the needle is changed [1].

Is the dose different at 65 or older?

The Wegovy injection schedule for adults starts at 0.25 mg weekly for weeks 1 to 4, then moves to 0.5 mg at weeks 5 to 8, 1 mg at weeks 9 to 12, and 1.7 mg at weeks 13 to 16, with maintenance from week 17 [1]. The recommended maintenance dose is 2.4 mg weekly (1.7 mg is also allowed). Adults who have tolerated 2.4 mg weekly for at least 4 weeks and need more weight loss may increase to a maximum of 7.2 mg weekly [1]. The label describes one adult schedule and a separate pediatric one, with no separate schedule for adults 65 and older [1].

What to watch for: stomach side effects and fluid loss

In three pooled placebo-controlled trials of Wegovy 2.4 mg in adults with obesity or overweight (2,116 on Wegovy, 1,261 on placebo), nausea occurred in 44% versus 16% on placebo, diarrhea in 30% versus 16%, vomiting in 24% versus 6%, constipation in 24% versus 11%, and dizziness in 8% versus 4%; 6.8% of Wegovy-treated patients stopped treatment because of adverse reactions versus 3.2% on placebo [1]. Those trials had a mean age of 48 years, so the rates describe a mostly middle-aged group rather than a 75-year-old [1].

The label's most relevant warning for a frail patient is acute kidney injury due to volume depletion. In the Wegovy program this occurred at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in patients with prior kidney impairment and during dose titration, and often after gastrointestinal fluid loss [1]. The label says to monitor renal function in patients reporting reactions that could lead to volume depletion [1].

What to watch for: blood pressure, heart rate and blood sugar

The label reports hypotension-related reactions in 1.3% versus 0.4% on placebo and syncope in 0.8% versus 0.2%, and it advises monitoring heart rate at regular intervals [1]. Mean heart rate rose 1 to 4 beats per minute, and a rise of 20 beats per minute or more occurred in 26% versus 16% on placebo [1].

Wegovy can increase the risk of low blood sugar when used with insulin or a sulfonylurea [1]. In adults with type 2 diabetes and a BMI of 27 or higher, glucose below 54 mg/dL occurred in 6.2% on Wegovy 2.4 mg versus 2.5% on placebo, and the risk was higher with a sulfonylurea; the label says to consider reducing the insulin or insulin secretagogue dose when starting Wegovy [1].

Semaglutide also delays gastric emptying and can change how oral medicines are absorbed. In a study with the semaglutide tablet, levothyroxine exposure rose 33%, and the label advises closer clinical or laboratory monitoring for narrow-therapeutic-index drugs [1].

Symptoms that need urgent attention

The boxed warning tells prescribers to counsel patients about thyroid tumor symptoms: a neck mass, difficulty swallowing, shortness of breath, persistent hoarseness [1]. Personal or family history of medullary thyroid carcinoma or MEN 2 is a contraindication [1].

The label says to discontinue Wegovy if pancreatitis is suspected, and describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting [1]. It also says to discontinue and promptly seek medical advice if a hypersensitivity reaction is suspected; anaphylaxis and angioedema have been reported [1]. Gallstones were reported in 1.6% versus 0.7% and cholecystitis in 0.6% versus 0.2% in adult weight-management trials, and gallbladder studies are indicated if gallstones are suspected [1]. Pulmonary aspiration during general anesthesia or deep sedation has been reported with GLP-1 receptor agonists, and the label instructs patients to tell healthcare providers about planned surgeries or procedures [1].

Missed doses and what happens after treatment ends

The missed-dose rule differs between semaglutide products. For Wegovy, the label says to give the missed dose if the next scheduled dose is more than 2 days away. After 2 or more consecutive missed doses, the label says to re-escalate from a lower dose [1].

Semaglutide has a half-life of about 1 week, so it stays in the body for roughly 5 to 7 weeks after the last 2.4 mg or 7.2 mg injection [1]. Weight regain after stopping is documented. In STEP 4, 803 adults who reached 2.4 mg after a 20-week run-in were randomized to continue or switch to placebo for 48 weeks; weight change from week 20 to week 68 was -7.9% with continued semaglutide versus +6.9% on placebo, a 14.8 percentage-point difference [3]. In an off-treatment extension of 327 STEP 1 participants, mean weight loss at week 68 was 17.3% with semaglutide versus 2.0% with placebo; a year after stopping, semaglutide participants had regained 11.6 percentage points, for a net loss of 5.6% from baseline at week 120 versus 0.1% on placebo [4].